Endo (NDOI) Repurchase of Stock : $-4 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Endo Repurchase of Stock?

Endo's Repurchase of Stock for the three months ended in Dec. 2024 was $0 Mil.

Endo's Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2024 was $-4 Mil.

Endo Repurchase of Stock Historical Data

The historical data trend for Endo's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo Repurchase of Stock Chart

Endo Annual Data

Trend

Dec22

Dec23

Dec24

Repurchase of Stock

-2.46

Endo Quarterly Data
	Jun23	Sep23	Dec23	Apr24	Sep24	Dec24
Repurchase of Stock	Get a 7-Day Free Trial			-	-	-4.22	-	-

Endo Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4 Mil.

Endo Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Endo's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Endo Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo Inc (OTCPK:NDOI) » Definitions » Repurchase of Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.endo.com

Endo Inc is a diversified pharmaceutical company. It has four reportable business segments: (1) Branded Pharmaceuticals, (2) Sterile Injectables, (3) Generic Pharmaceuticals and (4) International Pharmaceuticals. Branded Pharmaceuticals segment includes a variety of branded products in the therapeutic areas of urology, orthopedics, etc. Sterile Injectables segment consists of branded sterile injectable products such as ADRENALIN, VASOSTRICT and APLISOL, among others. Generic Pharmaceuticals segment includes a product portfolio including patches, solid oral extended-release products, etc. Key revenue is generated from International Pharmaceuticals segment includes a variety of specialty pharmaceutical products, including OTC products, sold outside the U.S.